|Bid||6.02 x 2900|
|Ask||6.26 x 1000|
|Day's Range||6.25 - 6.39|
|52 Week Range||5.11 - 8.16|
|Beta (5Y Monthly)||0.31|
|PE Ratio (TTM)||69.34|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||11.00|
Subscribe to Yahoo Finance Plus to view Fair Value for KMDALearn more
View more earnings on KMDASee more from BenzingaClick here for options trades from BenzingaImara Changes Primary Endpoint In Mid-Stage Sickle Cell Disease TrialRegeneron Extends Hearing Loss Gene Therapy pact With Decibel© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Kamada (KMDA) delivered earnings and revenue surprises of -166.67% and 8.60%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
2021 Global Revenue of the Portfolio Acquired from Saol Therapeutics is Estimated Between $40 Million to $45 Million, with Approximately 75% and 20% of Sales Generated from U.S. and Canada, Respectively Acquisition Advances Kamada's Strategy of Evolving Into a Fully-Integrated Specialty Plasma Company with Strong Commercial Capabilities in the U.S.; Kamada’s Wholly-Owned U.S. Subsidiary, Kamada Inc, will be Responsible for the Commercialization of the Products in the U.S. MarketTransaction is Im